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Background: Clostridium difficile infection (CDI) is the leading cause of healthcare-associated diarrhea, and several
outbreaks with increased severity and mortality have been reported. In this study we report a C. difficile PCR
ribotype 027 outbreak in Portugal, aiming to contribute to a better knowledge of the epidemiology of this agent in
Europe.
Methods: Outbreak report with retrospective study of medical records and active surveillance data of all inpatients
with the diagnosis of CDI, from 1st January to 31th December 2012, in a Portuguese hospital. C. difficile isolates were
characterized regarding ribotype, toxin genes and moxifloxin resistance. Outbreak control measures were taken,
concerning communication, education, reinforcement of infection control measures, optimization of diagnosis and
treatment of CDI, and antibiotic stewardship.
Results: Fifty-three inpatients met the case definition of C. difficile-associated infection: 55% males, median age was
78.0 years (interquartile range: 71.0-86.0), 75% had co-morbidities, only 15% had a nonfatal condition, 68% had at
least one criteria of severe disease at diagnosis, 89% received prior antibiotherapy, 79% of episodes were nosocomial.
CDI rate peak was 13.89/10,000 bed days. Crude mortality rate at 6 months was 64.2% while CDI attributable cause
was 11.3%. Worse outcome was related to older age (P = 0.022), severity criteria at diagnosis (leukocytosis (P = 0.008)
and renal failure), and presence of fatal underlying condition (P = 0.025). PCR ribotype 027 was identified in 16 of 22
studied samples.
Conclusions: This is the first report of a 027-CDI outbreak in Portugal. We emphasize the relevance of the measures
taken to control the outbreak and highlight the importance of implementing a close and active surveillance of CDI.
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Clostridium difficile is an environmental organism that
may be carried asymptomatically in the human intestine,
or cause disease in susceptible persons. Those include in-
dividuals with disturbed intestinal flora, especially due to
recent use of broad-spectrum antibiotics, and/or im-
munocompromised patients. Also, the risk of C. difficile
infection (CDI) is higher among elderly patients who had
recent contact with healthcare settings [1-4]. Symptoms
of CDI range from mild diarrhea to pseudo-membranous
colitis, toxic mega colon or even death. CDI is presently* Correspondence: monica.oleastro@insa.min-saude.pt
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unless otherwise stated.the leading cause of healthcare-associated diarrhea in
Europe and in North America, representing an enormous
clinical and economic burden [5]. It is also an emerging
pathogen in the community, and is spreading as well to
animals used in food industry [6].
Since 2003, large outbreaks of more severe CDI-
associated disease, with higher relapse rates and in-
creased mortality have been reported in North America
and Europe, which have been attributed to strains of C.
difficile belonging to ribotype 027 [7]. These strains were
shown to be resistant to fluoroquinolones [3], and dis-
played genetic mutations in a toxin regulator gene (tcdC)
causing higher expression of toxins A and B, and pro-
duced a binary toxin [8,9]. Nevertheless, the contributionl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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yet to be clarified.
Recently, a large hospital-based survey conducted be-
tween 2008 and 2009, involving 106 laboratories in 34
European countries, showed that ribotype 027 was not
included among the most prevalent European types, with
its overall prevalence showing a slight decrease since the
last study (5%) [10]. In that survey, the 027 ribotype was
not detected among the isolates from Portuguese pa-
tients, but only 12 isolates were studied.
This study reports the first outbreak of C. difficile due
to ribotype 027 strain in a Portuguese hospital, aiming to
contribute to a better knowledge of the epidemiology of
this agent in Europe, and discusses the bundle of out-
break control measures taken.
Methods
The present study was considered a retrospective ana-
lysis of medical records in the context of an outbreak in-
vestigation. Therefore, its execution was communicated
to the Ethics Committee of the Centro Hospitalar do Al-
garve (CHA), but no ethical approval was required.
Setting
This study was conducted in the Centro Hospitalar do Al-
garve (CHA), which is a regional secondary hospital in
the South of Portugal, with a capacity of 330 beds, includ-
ing 40 beds (part of the Internal Medicine Department)
located separately, 17 km away from the main building. It
serves a population of about 170,000 inhabitants and has
an Intensive Care unit (12 beds) and Oncology and
Haematology Outpatient units (excluding acute leukemia
and bone marrow transplant patients). During the year of
2012, the hospital recorded 15 716 inpatient admissions,
with a mean length of stay of 7.17 days.
The CHA comprises an Infection Control Program and
Infection Control Team (ICT) and written guidelines for
the prevention and treatment of CDI since 2008 that are
reviewed every 3 years, as well as for the management of
outbreaks. The subject “CDI” is discussed every year in
the educational activities for the healthcare workers
(HCW) and active surveillance of CDI is conducted since
2009, with a mean incidence rate below 2/10,000 patient
bed days until the end of the 1st trimester of 2012.
Data collection and population
We conducted a retrospective study of the medical records
and active surveillance data collected by the ICT of all in-
patients with the diagnosis of CDI in CHA, during the
period from 1st January to 31th December 2012. Demo-
graphic, epidemiological and clinical data, co-morbid con-
ditions, antibiotics and proton pump inhibitors (PPI)
consumption within the three months prior to diagnosis of
CDI, as well as treatment, rate of relapse and 30 day crudeand attributable mortality, were registered and analysed in
a Microsoft EXCEL™ database.
Definitions
For case definition, severe disease criteria, and treatment
guidelines, the European Society of Clinical Microbiol-
ogy and Infectious Diseases (ESCMID) treatment guid-
ance for C. difficile infection was used [11].
CDI onset classification was defined according to the
time of symptom onset and timing of hospitalization in
CHA, as summarized elsewhere [12,13].
The Mccabe score was used to evaluate the vital prog-
nosis of the underlying clinical situation, and comprises
three categories: nonfatal disease (five year survival not
affected by underlying disease), ultimately fatal (not ex-
pected to survive more than five years) and rapidly fatal
(not expected to survive more than one year) [14].
The incidence rate was calculated as the number of
cases per 10,000 patient bed days, according to the stud-
ies conducted by the ESCMID [10].
Outbreak control measures
In April 2012, when the CDI outbreak was declared in the
hospital, the ICT Coordinator assumed the leadership of
the Outbreak Control Team (OCT), and a bundle of out-
break control measures were taken, concerning five main
areas [15,16] – communication, education, reinforcement
of infection control measures, optimization of diagnosis
and treatment of CDI, and antibiotic stewardship, as fol-
lows: i) Communication of the outbreak to local, regional
and national public health authorities, with weekly up-
dated reports in the first three months and monthly after-
wards, until January 2013; ii) establishment of a network
with the Regional Infection Control Group, assuring that
the same control measures were adopted by the two main
hospitals and all other primary care ambulatory and in-
patient institutions, and that all healthcare workers in-
volved received education on the diagnosis, treatment and
prevention of CDI; iii) communication via e-mail to all
nurse and medical ward leaders, as well as intranet com-
munication at hospital level to inform all healthcare
workers of the outbreak, with epidemiological and clinical
explanations of the situation; iv) implementation of a bun-
dle of infection control measures according to the institu-
tion guidelines, based on several issued international
guidelines [12,17-19] - universal precautions including
hand hygiene with soap and water and gloves and aprons
use, contact isolation precautions including admission to
individual room if available or cohorting of confirmed
cases (two and three bed rooms), cleaning and disinfect-
ing of wards and equipment every eight hour shift with
sodium hypochloride (5,000 ppm concentration) and,
after discharge of the patient, peroxide hydrogen
vaporization; v) reinforcement of the knowledge of CDI
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with providing educational written material to patients
and visitors; vi) implementation of a protocol of proce-
dures in all patients presenting with diarrhea, for an early
identification of suspected cases of CDI, including identi-
fication of severity criteria and treatment algorithm when
confirmed; vii) confirmed toxin positive samples were
sent to the National Reference Laboratory of the Portu-
guese National Institute of Health (NIH) for strain culture
typing; viii) antibiotic stewardship - clinicians were
reminded to resume their prescriptions of antibiotics and
PPIs to those strictly indicated and to adequate the length
of antibiotherapy to the clinical situation, and were specif-
ically asked to reduce their prescriptions of quinolones
and 3rd generation cephalosporins. The ICT evaluated the
compliance to the antibiotic stewardship comparing the
consumption of these classes of antibiotics in the hospital
before, during and after the outbreak (Figure 1).
Laboratory diagnosis of Clostridium difficile infection
The fecal toxin was determined using the Vidas C. difficile
Tox A and B assay (bioMérieux, Marcy-l’Etoile, France).
Clostridium difficile culture and strains’ characterization
From 1st July 2012, diarrheal faecal samples of patients
hospitalized in different affected wards, with a positive
toxin test, were sent to the NIH reference laboratory.
The faecal samples were cultured, after ethanol shock,
on the chromogenic medium chromID® C. difficile (bio-
Mérieux, Marcy l’Etoile, France), under anaerobic condi-
tions. C. difficile-suspected colonies were obtained from
all patients, which were identified with the Rapid ID32
A galleries (bioMérieux), and confirmed by detection of
gluD gene, which encodes the glutamate dehydrogenase
specific for C. difficile [20].
The isolates were further characterized by capillary gel
electrophoresis-based PCR ribotyping, as well as by PCR2012, 
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Figure 1 Evolution of the consumption of ceftriaxone and levofloxaci
of 2013.detection of enterotoxin A and cytotoxin B (tcdA and
tdcB genes, respectively), binary toxin (cdtA and cdtB
genes), and the deletion in the tcdC gene [21,22]. The
susceptibility to moxifloxacin was determined by E-Test®
(bioMérieux).
Statistical analyses
Non normally distributed variables were compared with the
Mann–Whitney test. Proportions were compared with the
χ2 test. The P values of <0.05 were considered significant.
Results
Patient’s characterization
From 1st January to 31th December 2012, a total of 53 in-
patients met the case definition of C. difficile-associated
infection.
Patient’s demographic characteristics are summarized
in Table 1 and the co-morbid conditions are displayed in
Figure 2A. Vital prognosis of the underlying clinical situ-
ation was evaluated according to the McCabe score, and
overall only eight out of 53 (15.1%) patients had a nonfa-
tal condition (Figure 2B).
Fifty patients (94.3%) had a positive toxin assay; of
these, 6.0% (three patients) had at least one negative
fecal toxin test in the seven days preceding the positive
test, and 18.0% (nine patients) in the preceding 30 days.
For these patients, the toxin test was repeated several
times due to the persistent diarrhea. For the remaining
three patients, CDI was diagnosed by means of detection
of pseudomembranous colitis by fibrosigmoidoscopy and
biopsy, since two of them had ileus, and the third one
had a negative toxin test, but a high clinical suspicion
[23]. The average time between patient’s admission and
CDI diagnosis was 17 days, varying from one day to a
maximum of 72 days.
Criteria for disease severity at the time of CDI diagnosis
were based on the ESCMID guidance document; 68.0%2012, 
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Table 1 Characteristics of the 53 patients with Clostridium
difficile-associated diarrhea during the outbreak period
Patients (n = 53) characteristics Number (%)
Males 29 (54.7%)
Median age in years (interquartile range) 78.0 (71.0-86.0)
Place of origin
Home 26 (49.1%)
Nursing home 11 (20.8%)
Long term care facility 16 (30.2%)
Hospital admission during the 6 previous
months
35 (66.0%)
Antimicrobial exposure within 3-months
before CDI diagnosis
47 (88.7%)
Gastric acid suppressors (Proton pump inhibitors)
intake within 3-months before CDI diagnosis
49 (92.5%)
Clinical outcome
Relapse 12 (22.6%)
Death at 6 months 34 (64.2%)
CDI Attributable cause 6 (11.3%)
CDI Contributing cause 19 (35.8%)
Unrelated 9 (17.0%)
CDI – Clostridium difficile infection.
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tosis were the most frequent (Figures 3A and 3B).
According to patient’s hospital medical records, 47
(88.7%) of the 53 cases had received antibiotics in the three
months prior to the diagnosis, and among these, all except
one had received two or more classes of antibiotics. The
most commonly used antibiotics were fluoroquinolones
(mainly ciprofloxacin) and penicillins in association with
clavulanic acid or tazobactam (59.6% each), cephalosporins
(36.2%), aminoglicosides (31.9%) and carbapenems (23.4%).
In addition, in the same period of time, 49 (92.5%) patients
had been prescribed with proton pump inhibitors.
Concerning the CDI onset, cases were classified ac-
cording to standardized published definitions [12,13],1
2
3
4
5
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Comorbid conditions
A B
32.1%
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Figure 2 Underlying comorbidity of the 53 patients with Clostridium
of each comorbid condition; B- Evaluation of the vital prognosis of thand were distributed as follows: 30 (56.6%) cases were
healthcare facility onset-healthcare facility associated
(HCFA), 12 (22.6%) were community onset-HCFA, four
(7.5%) cases were community onset, and seven (13.2%)
cases had an indeterminate onset.
Incidence rates and epidemic curve
The CDI rate, calculated as the number of CDI cases per
10,000 patient bed days, increased from 1.09, in January
2012, to 8.23 in April 2012, when the outbreak was de-
clared, with a peak of 13.89 in June 2012, with a decreasing
trend afterwards. The epidemic curve of the outbreak, as
well as the incidence curves in the previous (2011) and fol-
lowing (2013) years, are displayed in Figure 4. The end of
the outbreak scenario was declared in 31st January 2013,
after three consecutive months in which the observed inci-
dence rate was similar to the pre-outbreak situation.
Treatment and clinical outcome
The global mortality within 30 days of the diagnosis of
CDI was 39.6% (21/53) and further 13 patients died
during the following 6 months, with a total crude mor-
tality of 64.2% (34/53). A total of 24 patients (45.3%)
died during the first CDI episode. From the 29 patients
who survived the first episode, 12 relapsed (41.4%;
22.6% overall relapse rate) and 10 of these eventually
died. After two independently clinical judgments, CDI
was considered the attributable cause of death in six
(17.6%; 11.3% overall attributable death) patients, a
contributing cause in 19 (55.9%) patients and unrelated
in nine (26.5%) cases.
The treatment of infected patients was established ac-
cording to CHA protocol, which is based in the ESCMID
guidelines [11]: 48 patients were treated either with
metronidazole (n = 18) or vancomycin (n = 19), or with
both vancomycin and metronidazole (n = 11); five pa-
tients did not receive treatment (four died before they
could start any treatment, and one patient with mild dis-
ease was dismissed and CDI resolved without treatment).0
0
0
0
0
0
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difficile-associated infection during the outbreak period: A – Rate
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Figure 3 Criteria for disease severity at the time of Clostridium difficile infection diagnosis: A – Rate of patients with no criteria or
unknown criteria versus the rate of patients with at least one criteria of severe disease; B – Number of patients with, without or
unknown status regarding the evaluated severity criteria: pseudomembranous colitis, ileus, leukocytosis, serum creatinine and
serum albumin.
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the group of patients treated with vancomycin only (9/19,
47.4%), followed by the patients treated with both antibi-
otics (5/11, 45.5%) and by those treated with metronida-
zole only (6/18, 33.3%).
The group with the highest recurrence rate was the
one treated with both metronidazole and vancomycinCD
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Figure 4 Incidence of Clostridium difficile infection cases during the o
previous year (2011) and following year (2013).(4/11; 36.4%), while recurrence rates were similar follow-
ing treatment with either metronidazole (5/18; 27.8%) or
vancomycin (5/19; 26.3%) (Figure 5).
In order to evaluate the CDI clinical burden, we com-
pared the 25 cases for which CDI was the direct cause of
(or contributed to) the death (group 1), with the cases for
which no death occurred (group 2) (n = 19). The median2.24
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that of group 2 (80.2 years; interquartile range 76 to 87
years versus 74.2 years; interquartile range 67 to 81 years;
P = 0.022). Other traits that differentiated these two
groups of patients concerned the severity of the under-
lying clinical situation, as well as the markers of severe
CDI, such as renal failure and leukocytosis [24]. Indeed,
taking into account the McCabe score, the rapidly fatal
condition was observed in 56.0% (n = 14) of the patients
of group 1, against 26.3% (n = 5) of the group 2 (P =
0.025). Also, both leukocytosis (19/25, 76% versus 6/19,
31.6%; P = 0.008) and renal failure (9/25; 36% versus 5/19;
26.3%; P > 0.05) were more frequent among group 1 than
among group 2. As previously mentioned, in some cases,
there was a considerable delay between patient’s admis-
sion and CDI diagnosis. Analyzing the two groups con-
cerning this parameter, we observed that the average time
for group 1 was 13.5 days (SD: 17.3) while for group 2 was
8.3 days (SD: 9.3), although this difference was not statisti-
cally significant.
Strain typing
Among the 22 samples that were sent to the NIH refer-
ence laboratory for culture and typing, 20 had a positive
faecal culture for C. difficile. Regarding the ribotype, 16
(72.7%) belonged to ribotype 027, and the remaining
four strains belonged to one of each ribotype, AI-84,
056, 020 and 014. All the studied isolates belonging to
ribotype 027 were detected from HCFA cases, while the
isolates from ribotypes 014 and AI-84 corresponded to
indeterminate onset cases.
All the isolates were positive for both the enterotoxin
A and the cytotoxin B encoding genes. Binary toxin gene
and the 18-bp deletion in the tcdC gene were present in
the all 027 isolates and absent in the other ribotypes.
The in vitro resistance to moxifloxacin was confirmed
for all 16 isolates of the 027 ribotype, (minimum inhibi-
tory concentration (MIC) ≥32 mg/L), while the other
non-027 ribotype isolates were susceptible to this anti-
biotic (MICs of 0.5 and 0.75 mg/L).Discussion
To date, little information is available concerning C. difficile
infection in Portugal. The few existing studies were pub-
lished in non-indexed national journals, and report data on
hospital casuistic. Nevertheless, they showed an important
increase on CDI cases, as well on mortality rates, over the
last five years. None of these studies identified the infecting
strain.
The C. difficile 027 ribotype strain implicated in this
outbreak showed traits that are common to the so called
hypervirulent strains of this ribotype, including the
known mutation in the tcdC gene and the presence of the
binary toxin. Also relevant is the reduced susceptibility to
fluoroquinolones of these strains, which likely contributes
to their rapid dissemination [25] compared to non-
outbreak isolates of the same type. Indeed, several studies
point to fluoroquinolones therapy as a risk factor for C.
difficile-associated disease during outbreaks [16,26-28]. In
the present cohort, 60% of the patients had a history of
recent fluoroquinolones consumption, which has likely
contributed to the spread of the epidemic strain, once it
was introduced in the hospital.
The antibiotic stewardship implemented after the out-
break was declared, with special focus on reduced pre-
scriptions of fluoroquinolones and third generation
cephalosporins (Figure 1), presumably contributed to the
progressive reduction in the incidence of CDI (Figure 4).
This fact highlights the value of this measure to control
nosocomial CDI, in agreement with previously published
studies [16,29,30].
It was not possible to trace how this epidemic ribotype
027 C. difficile strain was introduced in the hospital, as
the first samples were not sent to the NIH for ribotyping,
hampering the identification of the index case. Moreover
we were not able to associate the presence of this strain
with the occurrence of other CDI cases in Portugal (out-
break or sporadic cases) probably due to the absence of a
functional notification system of this disease. Neverthe-
less, it is worthwhile to underline the implication of C.
difficile 027 strain in the present outbreak, in contrast to
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the prevalence of this strain in favor of another emergent
ribotypes [10].
To date there is no consensus regarding the association
of C. difficile ribotype 027 strains with more serious clin-
ical outcome. Indeed, while most of the hospitals with
027 strain outbreaks have reported increased severity of
the associated-disease, others are showing no difference
to other ribotypes [16,31,32].
In the outbreak here described, 68% of the patients had
at least one criterion of severe disease at diagnosis. Also,
mortality occurred at high rate, with a 30-day all-cause
mortality of 39.6% and a 027-CDI-related mortality rate
of 18%, which is considerable higher than that reported
in other 027-associated outbreaks [16,33-36]. Neverthe-
less, our data suggests that, besides the infecting strain
and its ability for rapid spreading when antibiotic pres-
sure is present, other factors have contributed to this dra-
matic mortality rate such as advanced age, co-morbidities
and the co-existence of rapidly fatal conditions.
Following antibiotic treatment for CDI, the highest
mortality rate occurred for the vancomycin-treated pa-
tients, followed by the patients treated with vancomycin
plus metronidazole, and the highest recurrence rate was
also observed for these patients, which was an unex-
pected finding [37]. The rationale for observing higher
rates of treatment failure with vancomycin is not clear,
but can be probably attributed to the fact that those pa-
tients had already a very poor prognostic, as also pointed
by Gravel et al. [38]. Also, the worse outcome for pa-
tients treated with vancomycin or both vancomycin and
metronidazole may be due to the clinical severity of CDI
which led to the choice of the treatment according to
published guidelines [23].
It is worth mentioning that we did not evaluate which
patients had received non-CDI antimicrobials during
and/or after C. difficile treatment, as well as differences in
antibiotic regimens. This likely implicated the disease out-
come, as previous highlighted [39].
Concerning the CDI onset classification, we point out
that patients classified as being CDI community onset,
all came from nursing homes or other long term care fa-
cilities, so all CDI cases should be considered healthcare
associated.
Aiming to control the outbreak, the ICT conducted an
investigation that identified several problems concerning
CDI patients, namely: previous and continuous excess
use of broad spectrum antibiotics and proton pump in-
hibitors, with no clear indication registered in the clinical
process; low level of clinical suspicion; and low sensibility
of the diagnostic test used, contributing to late diagnosis
of CDI, and consequently to a delay in the establishment
of therapy and to a late implementation of control mea-
sures. In this context, it is worth emphasizing that thelaboratory diagnosis of CDI was performed with a stand-
alone rapid enzyme immunoassay for the C. difficile
toxins, which has originated a number of false negative re-
sults, hampering the management of the CDI [40]. In
addition, at the beginning of the outbreak investigation,
the OCT detected that in some cases clinicians did not
registered severity criteria of CDI. Notably the presence of
renal failure and leukocytosis were not always adequately
valorized. A recent study showed that both these clinical
conditions are predictors of severe CDI if measured on
the day of diagnosis [24]. To correct these findings, a
protocol for the initial evaluation and treatment of all pa-
tients with diarrhea was implemented since May 2012.
It should also be pointed out the lack of awareness and
knowledge of the institutional guidelines by the hospital
staff, especially among clinicians, indicating the need of a
different approach to motivate HCW in infection control
educational activities, which are not mandatory in
Portugal. The bundle of measures that were taken tried
to face and correct the detected problems, together with
the involvement of all HCW in their resolution.
We therefore considered that all these constraints, to-
gether with the presence of a hypervirulent strain with a
high spread capacity, contributed to the increased risk of
nosocomial transmission and to the severity of CDI epi-
sodes observed in this outbreak.Conclusion
In conclusion, regarding the infecting strain, while the
high potential for spreading of 027 strains seems clear,
further investigation on epidemic strains can be a use-
ful contribution to shed some light on the virulence
and epidemic potential of C. difficile 027, in accord-
ance with recent studies suggesting that subtypes may
influence the severity of clinical outcome.
High level suspicion and early diagnosis of CDI, with
initial correct evaluation of severity criteria, and ad-
equate treatment according to this evaluation, together
with the reinforcement of a bundle of infection control
measures is necessary to avoid the spread of C. difficile.
Antibiotic stewardship is perhaps the most important
isolated measure that can be taken to prevent CDI re-
lated clinical burden, but it is difficult to accomplish in
a growing population of elderly, dependent and institu-
tionalized patients with consecutive healthcare associ-
ated infections.
Finally, this is the first outbreak of C. difficile due to ribo-
type 027 strain that is reported in Portugal, highlighting the
importance of implementing a close surveillance of CDI in
Portugal, both at population-based and nosocomial levels.Competing interests
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